Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 756 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC MOST POPULAR HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... August 7, 2023 Lessons from the green: How sports psychology helped a top golf... March 16, 2023 Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... July 21, 2023 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Load more HOT NEWS FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported...
